Get the Stockscreener App
584.49
5.82%
32.02
Madrigal Pharmaceuticals Inc stock is traded at $584.49, with a volume of 160.59K.
It is up +5.82% in the last 24 hours and up +7.96% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$552.47
Open:
$559.13
24h Volume:
160.59K
Relative Volume:
0.48
Market Cap:
$13.33B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-23.27
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-1.09%
1M Performance:
+7.96%
6M Performance:
+98.62%
1Y Performance:
+90.71%
1-Day Range:
$554.00
$589.67
1-Week Range:
$546.20
$593.00
52-Week Range:
$265.00
$605.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
586.75 | 12.55B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.01 | 112.81B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
740.86 | 76.32B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
888.79 | 54.80B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
409.00 | 53.43B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
194.47 | 40.49B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals (MDGL) Sees Price Target Increase By B. Riley Securities | MDGL Stock News - GuruFocus
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data - Insider Monkey
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Madrigal Pharmaceuticals Expands Workforce With New Equity Grants to Staff - MyChesCo
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockCash Flow Trends & Exceptional Capital Investment - earlytimes.in
Madrigal Pharmaceuticals (MDGL): Rezdiffra’s Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation - Yahoo Finance
Why analysts remain bullish on Madrigal Pharmaceuticals Inc. stockGap Down & Entry and Exit Point Strategies - Newser
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $2,413,412.82 in Stock - MarketBeat
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing - marketscreener.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock By Investing.com - Investing.com Australia
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potentialPrice Action & Stepwise Entry/Exit Trade Alerts - Newser
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Lobbying Update: $30,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Schroder Investment Management Group Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by New York State Common Retirement Fund - MarketBeat
Can Madrigal Pharmaceuticals Inc. (YDO1) stock double in coming yearsWall Street Watch & Stock Portfolio Risk Control - Newser
Legal & General Group Plc Increases Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock valuation compares with sectorWeekly Trade Review & Real-Time Buy Signal Notifications - Newser
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth story2025 Technical Patterns & Free Community Consensus Stock Picks - Newser
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing - marketscreener.com
MDGL: Billion-dollar run rate, expanding prescriber base, and robust pipeline drive long-term growth - TradingView
Russell Investments Group Ltd. Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikesJuly 2025 Pullbacks & High Accuracy Investment Signals - Newser
Madrigal Pharmaceuticals (MDGL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Insider Monkey
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Swiss National Bank - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Franklin Resources Inc. - MarketBeat
Madrigal Pharmaceuticals Inc (YDO1.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why (MDGL) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Groupama Asset Managment Purchases 7,439 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Creative Planning Lowers Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by American Century Companies Inc. - MarketBeat
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Why Madrigal Pharmaceuticals (MDGL) Is Up 8.9% After Positive Two-Year Rezdiffra Data in MASH Cirrhosis - Sahm
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress? - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Why retail traders accumulate Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Support & Resistance & Precise Swing Trade Alerts - moha.gov.vn
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Is Madrigal Pharmaceuticals Inc. stock vulnerable to regulatory risks2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
Entropy Technologies LP Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough - MyChesCo
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):